KR20190127691A - 고혈압의 치료를 위한 조성물 - Google Patents

고혈압의 치료를 위한 조성물 Download PDF

Info

Publication number
KR20190127691A
KR20190127691A KR1020197024682A KR20197024682A KR20190127691A KR 20190127691 A KR20190127691 A KR 20190127691A KR 1020197024682 A KR1020197024682 A KR 1020197024682A KR 20197024682 A KR20197024682 A KR 20197024682A KR 20190127691 A KR20190127691 A KR 20190127691A
Authority
KR
South Korea
Prior art keywords
dose
pharmaceutical composition
lowest
diuretic
calcium channel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197024682A
Other languages
English (en)
Korean (ko)
Inventor
안토니 로드겔스
스테판 맥마혼
Original Assignee
더 조지 인스티튜트 포 글로벌 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 조지 인스티튜트 포 글로벌 헬스 filed Critical 더 조지 인스티튜트 포 글로벌 헬스
Priority to KR1020247019312A priority Critical patent/KR20240096848A/ko
Publication of KR20190127691A publication Critical patent/KR20190127691A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197024682A 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물 Ceased KR20190127691A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247019312A KR20240096848A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762450324P 2017-01-25 2017-01-25
US62/450,324 2017-01-25
PCT/IB2018/000083 WO2018138578A1 (en) 2017-01-25 2018-01-23 Compositions for the treatment of hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247019312A Division KR20240096848A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물

Publications (1)

Publication Number Publication Date
KR20190127691A true KR20190127691A (ko) 2019-11-13

Family

ID=62979058

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197024682A Ceased KR20190127691A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물
KR1020257021924A Ceased KR20250107955A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물
KR1020247019312A Ceased KR20240096848A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물
KR1020257011127A Ceased KR20250052479A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257021924A Ceased KR20250107955A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물
KR1020247019312A Ceased KR20240096848A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물
KR1020257011127A Ceased KR20250052479A (ko) 2017-01-25 2018-01-23 고혈압의 치료를 위한 조성물

Country Status (21)

Country Link
US (8) US10322117B2 (enExample)
EP (6) EP3573620B1 (enExample)
JP (4) JP2020506180A (enExample)
KR (4) KR20190127691A (enExample)
CN (4) CN116327958A (enExample)
AU (3) AU2018213147B2 (enExample)
CA (1) CA3051374A1 (enExample)
DK (2) DK4101454T3 (enExample)
ES (2) ES2981657T3 (enExample)
FI (2) FI3573620T3 (enExample)
HR (2) HRP20230267T1 (enExample)
HU (2) HUE067617T2 (enExample)
LT (2) LT3573620T (enExample)
MX (2) MX2019008813A (enExample)
PL (2) PL4101454T3 (enExample)
PT (2) PT4101454T (enExample)
RS (2) RS64042B1 (enExample)
RU (1) RU2019126749A (enExample)
SI (2) SI3573620T1 (enExample)
TW (5) TW202508572A (enExample)
WO (1) WO2018138578A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155479A (ko) 2024-04-23 2025-10-30 신풍제약주식회사 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
HRP20230267T1 (hr) 2017-01-25 2023-06-09 The George Institute for Global Health Pripravci za liječenje hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
WO2020041864A1 (en) * 2018-08-25 2020-03-05 Crd Pharmaceuticals Inc. Synchronize hypertensive therapy with circadian rhythm
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CN113616651B (zh) * 2020-05-08 2023-12-29 深圳奥萨制药有限公司 一种复方降压药物组合物及其应用
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
EP4574148A1 (en) 2023-12-20 2025-06-25 KRKA, d.d., Novo mesto Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
CA2406077C (en) 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
KR20060120126A (ko) 2003-10-20 2006-11-24 노파르티스 아게 심혈관계 이환상태를 감소시키기 위한 베나제프릴 및암로디핀
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
US20070191438A1 (en) 2004-04-06 2007-08-16 Rohrer Susan P Methods for the treatment of hypertension
PL1814527T5 (pl) 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
KR100582347B1 (ko) 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
CN101454006B (zh) 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
KR20090057538A (ko) * 2007-12-03 2009-06-08 박사룡 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물
CN101450211A (zh) * 2007-12-07 2009-06-10 上海艾力斯医药科技有限公司 复方降压制剂
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN101966187A (zh) * 2009-07-14 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和厄贝沙坦的复方制剂
CN101618215A (zh) 2009-08-16 2010-01-06 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
BR112012028153A2 (pt) 2010-05-03 2018-08-07 Tsh Biopharm Corporation Ltd composição farmacêutica e método para o tratamento de hipertensão
WO2011149438A1 (en) * 2010-05-28 2011-12-01 Mahmut Bilgic Combination of antihypertensive agents
CN101966190A (zh) * 2010-07-17 2011-02-09 邬林祥 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
CN102225203A (zh) * 2011-06-29 2011-10-26 北京阜康仁生物制药科技有限公司 一种用于降低血压的药用组合物
CN102327263B (zh) 2011-07-06 2013-03-06 宁夏康亚药业有限公司 复方降压药物组合物及复方降压片剂
CN102327272B (zh) 2011-07-14 2013-08-14 海南锦瑞制药股份有限公司 一种口服固体药用组合物及其制备方法
US10918612B2 (en) * 2013-01-22 2021-02-16 Markus Zwickl Combinations with 2-aminoethanesulfonic acid
US9839644B2 (en) * 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
CZ2015687A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
CN106074418A (zh) 2016-06-23 2016-11-09 南京华宽信息咨询中心 一种治疗高血压的苯磺酸氨氯地平片及其制备方法
CN106310278A (zh) * 2016-08-01 2017-01-11 深圳奥萨制药有限公司 一种含叶酸的多联降压药物组合物
US10369156B2 (en) 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
HRP20230267T1 (hr) 2017-01-25 2023-06-09 The George Institute for Global Health Pripravci za liječenje hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
JP7474738B2 (ja) 2018-07-26 2024-04-25 ザ ジョージ インスティテュート フォー グローバル ヘルス 高血圧症の処置のための組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155479A (ko) 2024-04-23 2025-10-30 신풍제약주식회사 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제

Also Published As

Publication number Publication date
EP4635566A2 (en) 2025-10-22
SI3573620T1 (sl) 2023-05-31
AU2025287416B2 (en) 2026-07-09
TW201831204A (zh) 2018-09-01
JP2020506180A (ja) 2020-02-27
RS64042B1 (sr) 2023-04-28
RU2019126749A (ru) 2021-02-26
US20230087834A1 (en) 2023-03-23
US12102623B2 (en) 2024-10-01
US20200397770A1 (en) 2020-12-24
ES2940316T3 (es) 2023-05-05
US20180243278A1 (en) 2018-08-30
RS65701B1 (sr) 2024-07-31
EP3573620A1 (en) 2019-12-04
EP4620524A2 (en) 2025-09-24
TW202023619A (zh) 2020-07-01
HUE061444T2 (hu) 2023-08-28
TW202319049A (zh) 2023-05-16
TW202421198A (zh) 2024-06-01
AU2025287416A1 (en) 2026-01-22
KR20250052479A (ko) 2025-04-18
EP4609913A2 (en) 2025-09-03
AU2018213147B2 (en) 2023-08-31
MX2023004366A (es) 2023-05-03
EP4635566A3 (en) 2026-01-07
HUE067617T2 (hu) 2024-11-28
EP4620524A3 (en) 2025-12-10
HRP20240701T1 (hr) 2024-09-27
WO2018138578A1 (en) 2018-08-02
US20260166019A1 (en) 2026-06-18
EP4101454A1 (en) 2022-12-14
AU2023274064A1 (en) 2023-12-14
ES2981657T3 (es) 2024-10-09
AU2023274064B2 (en) 2026-01-15
KR20250107955A (ko) 2025-07-14
US12673047B2 (en) 2026-07-07
LT3573620T (lt) 2023-04-11
TW202508572A (zh) 2025-03-01
EP4609913A3 (en) 2025-11-12
US20260027093A1 (en) 2026-01-29
US20230381161A1 (en) 2023-11-30
LT4101454T (lt) 2024-07-25
CN120585831A (zh) 2025-09-05
US20190343818A1 (en) 2019-11-14
JP7905274B2 (ja) 2026-08-14
US20250312325A1 (en) 2025-10-09
RU2019126749A3 (enExample) 2021-08-30
FI3573620T3 (fi) 2023-03-25
JP2026104977A (ja) 2026-06-25
JP2025010535A (ja) 2025-01-21
SI4101454T1 (sl) 2024-10-30
CA3051374A1 (en) 2018-08-02
AU2018213147A1 (en) 2019-09-19
DK4101454T3 (da) 2024-06-17
PT3573620T (pt) 2023-03-20
HRP20230267T1 (hr) 2023-06-09
EP4374915A2 (en) 2024-05-29
US11478462B2 (en) 2022-10-25
EP3573620A4 (en) 2020-11-25
TWI852279B (zh) 2024-08-11
PL4101454T3 (pl) 2024-07-29
TWI825279B (zh) 2023-12-11
FI4101454T3 (fi) 2024-06-10
KR20240096848A (ko) 2024-06-26
EP3573620B1 (en) 2022-12-14
US10799487B2 (en) 2020-10-13
US12285415B2 (en) 2025-04-29
PL3573620T3 (pl) 2023-04-24
CN119386015A (zh) 2025-02-07
EP4374915A3 (en) 2024-07-31
US12465599B2 (en) 2025-11-11
PT4101454T (pt) 2024-06-17
JP2023063282A (ja) 2023-05-09
CN110545819A (zh) 2019-12-06
DK3573620T3 (da) 2023-03-20
BR112019015368A2 (pt) 2020-03-10
CN116327958A (zh) 2023-06-27
EP4101454B1 (en) 2024-04-10
MX2019008813A (es) 2020-02-12
US10322117B2 (en) 2019-06-18

Similar Documents

Publication Publication Date Title
US12465599B2 (en) Compositions for the treatment of hypertension
JP2026031933A (ja) 高血圧症の処置のための組成物
HK40116862A (en) Compositions for the treatment of hypertension
HK40092202A (en) Compositions for the treatment of hypertension

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190822

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210121

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230412

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231006

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230412

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231006

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230609

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210121

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240407

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20240311

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20231006

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230609

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230412

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210121

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240610